Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

Area of Science:

• Regenerative Medicine
• Stem Cell Therapy
• Cardiovascular Research

Background:

• Ischemic diseases pose a significant global health burden, leading to high morbidity and mortality.
• Mesenchymal stem cells (MSCs) are being investigated for their therapeutic potential in various ischemic conditions.
• Current research highlights the safety and symptomatic relief offered by MSC therapy in clinical trials.

Purpose of the Study:

• To review the current status and therapeutic potential of MSC-based treatments for major ischemic diseases.
• To discuss critical factors influencing the efficacy of MSC transplantation.
• To evaluate MSCs as an ideal therapeutic option for ischemic disease patients.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies on MSC therapy for ischemic diseases.
• Analysis of factors affecting MSC therapeutic efficacy, including delivery routes, cell survival, and patient-specific conditions.
• Synthesis of current evidence for ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot.

Main Results:

• MSC therapy has demonstrated safety and symptom relief in patients with ischemic diseases.
• Therapeutic efficacy is influenced by crucial factors such as delivery method, MSC survival rates, transplantation timing, microenvironment, and patient health.
• Published data supports the potential of MSCs in managing conditions like ischemic cerebrovascular disease, ICM, and diabetic foot.

Conclusions:

• Mesenchymal stem cell transplantation presents a promising and potentially ideal therapeutic strategy for patients suffering from various ischemic diseases.
• Further research and optimization of delivery and patient selection are essential to fully realize the benefits of MSC therapy.
• MSC-based approaches offer significant potential for improving outcomes in ischemic cerebrovascular disease, ICM, and diabetic foot management.